Serum Institute of India

Serum Institute of India Pvt. Ltd. is the world's largest vaccine manufacturer by the number of doses produced, having distributed over 1.3 billion doses globally. The company specializes in developing and manufacturing a range of life-saving vaccines, including those for Polio, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, and Covid-19. Approximately 65% of children worldwide receive at least one vaccine produced by the Serum Institute, which is accredited by the World Health Organization and utilized in national immunization programs across around 140 countries. By employing modern genetic and cell-based technologies, the Serum Institute aims to provide affordable immunobiologicals, thereby significantly contributing to public health and saving millions of lives globally.

Natasha Poonawalla

Director

9 past transactions

JetSynthesys

Venture Round in 2025
JetSynthesys is a pioneering digital technology company focused on developing innovative products, platforms, and services. It aims to reach every household member digitally by leveraging powerful targeted big data analytics and compelling content experiences.

Hervolution Therapeutics

Series A in 2024
Hervolution Therapeutics specializes in developing first-in-class immunotherapies targeting tumors by harnessing Human Endogenous Retroviral proteins (HERVs). The company pioneers innovative biotechnology solutions to combat hidden enemies within the human body.

IntegriMedical

Corporate Round in 2024
IntegriMedical is a global manufacturer specializing in original equipment for medical devices. The company focuses on the development and production of innovative needle-free drug delivery systems, specifically designed for patients who experience needle phobia. Utilizing advanced high-velocity jet stream technology, IntegriMedical's products administer RNA-based biologics and drugs through intramuscular and subcutaneous methods. These devices are engineered to enhance patient comfort and safety, significantly reducing pain associated with traditional injections. Compact and portable, IntegriMedical's solutions aim to facilitate ease of use for both patients and healthcare professionals.

Codagenix

Series B in 2023
Codagenix Inc., established in 2009 and headquartered in Farmingdale, New York, specializes in developing live-attenuated viral vaccines using its proprietary Synthetic Attenuated Virus Engineering (SAVE) platform. This technology involves the rational design of entire viral genomes via synthetic biology to create safe and effective vaccines for various human diseases such as influenza, dengue, respiratory syncytial virus, polio, and others. Additionally, Codagenix offers agricultural and companion animal vaccines.

Oxford Biomedica

Post in 2021
Oxford Biomedica is a biopharmaceutical company focused on gene and cell therapy, specializing in the development, manufacturing, and advancement of lentiviral vector-based medicines and related cell therapies. The company leverages its LentiVector platform to deliver therapeutic genes into non-dividing cells and collaborates with major pharmaceutical firms to progress both internal candidates and externally funded programs. Its internal pipeline targets diseases of the eye and the central nervous system, while ongoing partnerships span multiple therapeutic areas across Phase I/II and beyond. Oxford Biomedica also operates as a contract development and manufacturing organization, offering viral vector development and manufacturing services through OXB Solutions. Founded in 1995 and headquartered in Oxford, United Kingdom, the company maintains a global collaboration network with industry and academic partners.

SCHOTT Poonawalla

Corporate Round in 2021
A manufacturer specializing in pharmaceutical containers made from neutral glass tubing. The company offers a range of parenteral packaging systems, including vials, pre-fillable syringes, ampoules, and cartridges.

X-Vax

Series A in 2019
X-Vax Technology is a biotechnology company established in 2015 and headquartered in Jupiter, Florida. Its primary focus is the preclinical and clinical development of vaccines targeting mucosal infections caused by pathogens, including herpes, influenza, tuberculosis, and HIV, which affect millions globally. X-Vax is known for its development of a herpes vaccine candidate based on a genetically altered HSV-2 virus, specifically designed to elicit a robust immune response by inducing antibodies that lead to the killing of infected cells. This innovative approach utilizes Fc receptor activating antibodies that facilitate antibody-dependent cell-mediated killing, aiming to provide effective protection against herpes types 1 and 2. Through its pioneering research, X-Vax intends to advance the field of vaccines and enhance immune responses against significant viral infections.

Visterra

Series C in 2017
Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Nanotherapeutics

Acquisition in 2017
Nanotherapeutics is a privately held specialty biopharmaceutical company with full product development, cGMP manufacturing capabilities, and a proprietary pipeline. The Company's technologies can be used with all drug types ranging from small molecules to proteins and peptides. These technologies can be employed with new chemical entities or with generic drugs and can be used with the spectrum of existing drug types ranging from small synthetic molecules to large recombinant macromolecules.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.